Richard Self worked in the aerospace sector for thirty years supporting the business with innovative systems solutions and matching technologies to business needs.
He then made the transition into academia in 2002, where he now has small teams of Undergraduate and Masters students researching to identify the best frameworks of questions for evaluating emerging and advanced technologies for gaining business value.
Richard is a regular invited keynote speaker at UK and international business conferences where he always provides the audience with the important questions for evaluating the business needs and technologies.
Dr. Mishra (Ex-Genentech, Ex-NCI, Ex-NIH) is the founding president and CEO of American Association for Precision Medicine (AAPM) and is leading research efforts focused on preventing & curing chronic diseases; not only treating the sick but also providing knowledge/tools to individuals to live longer, healthier lives. He is also founder and CEO of Agility Pharmaceuticals, a pharmaceutical company committed to revolutionizing drug discovery & development through technology, big data, robotics, and artificial intelligence. He is a serial entrepreneur who founded his first company after graduating high school, and second company during his PhD. Since then, he has accumulated a wealth of experienced by building, investing and advising numerous other companies. He is an investor/co-founder/board member of a few US based corporations focused on accelerating drug discovery & development, blockchain and digital health. Widely recognized as a thought leader in the field of ‘technology and healthcare’, Dr. Mishra has keynoted, chaired, curated and organized numerous successful international conferences. Prior to Agility Pharma, Dr. Mishra served as a Scientist and Principal Investigator at the pharma giant Genentech, Roche. Where he participated in several drug discovery project teams. He also lead the efforts to establish robotic automation (robotization) driven mammalian cell based phenotypic screening capabilities and hit to lead identification efforts within Genentech. Moreover, his passion for drug development and precision medicine has led to identification of new drug targets, biomarkers, companion diagnostics and several drugs/ combinations in the clinic. His research work has been recognized globally by over 40 prestigious awards and honors. Due to his unique perspective & selfless service, he is highly respected & sought-after mentor to many. The companies that he has advised have raised multimillion dollars. Notably, he serves as a mentor and advisor to startup accelerators such as IndieBio, Health2.0’s Project Zygote (digital health accelerator) and California Life Sciences